So we’re absolutely tracking all of these areas currently and opportunity to spend.
Josh Jennings: Great. Thanks for that. And just I think the press release your team has called out a TAM for DrugSorb for the ticagrelor removal indication. The US and Canada, around $650 million. It seems like a little bit of a tick-up. Is there any new market analysis or is that the addition of Canada into that TAM. But just wanted to just regroup on the TAM that you guys are putting forward for ticagrelor removal indication? Thanks so much.
Phil Chan: Yeah, that — absolutely, it’s an — I’ll have Micah’s comment on this because it was his team that actually led that market analysis. But it’s very interesting. Canada is a country that uses ticagrelor very frequently. Even though Canada has a smaller population than the United States, it represents a substantial market. Effient, which is one of the competitors is no longer distributed in Canada. I think Eli Lilly was the company that was initially distributing it. And Plavix and the Canadian guidelines has highlighted that Brilinta is the preferred drug over Plavix based on clinical outcomes in these surgical patient. So the ticagrelor is actually used quite widely in Canada. And in particular, the use of dual anti-platelet therapy is widely used as well, given that it’s often used as a temporizing measure to help try to improve clinical outcomes while patients are traveling to — from faraway distances to major cardiac centers in major cities within Canada.
So it does represent a very exciting market for us. And I’ll turn it over to Micah to comment and maybe you can comment on contribution to the STAR-T trial. Makis?
Efthymios Deliargyris: Yes. Thank you, Phil. Yes, just exactly as Phill said, there’s a system of care in Canada that’s very harmonized across the country. National protocols, the national guidelines tend to be universally followed which is a little different than a very regional kind of practice that was seek in the US, where you can see variability in different geographic regions and between academic versus nonacademic centers. Canada, it tends to be a more universal treatment approach. And with ticagrelor, comparing the highest recommendation that has been adopted in the treatment protocols of acute coronary syndrome. So very high penetration, dominant position of ticagrelor in Canada. And then what we knew was happening based on this information, we validated in the STAR-T trial.
The enrollment rate and if you follow the trial closely, you saw that we did a really a very high pace towards the end, and we finished the trial actually with extra patients ahead of our own internal projections. That was because of the numbers that came in from Canada. So those patients are abundant. Their institutions are — have very high volume, so they encourage them almost on a daily basis. They have patients like these that they need to do work around the delays. So the trial was very popular, the patients were abundant, and the enrollment rates were very . We think the addition of Canada, our initial TAM analysis brings the substantial upside that you see in the subtext of your question that you noted.
Phil Chan: Appreciate it. Thank you.
Operator: And we have no further questions at this time. I will now turn the call back to Dr. Phillip Chan for closing remark.
Phil Chan: Well, thank you, everyone, for taking the time to get on this call today. Hopefully, it was a productive session for you. We look forward to the next update on the next call. Thanks so much, everyone. Have a good night.
Operator: And ladies and gentlemen, this concludes today’s call, and we thank you for your participation. You may now disconnect.
